Glial Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLL048 MIFTS: 52	Glial Tumor Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor ⁵⁸

Glioma ⁵⁸

Characteristics:

Orphanet epidemiological data:

⁵⁸

glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

MESH via Orphanet ⁴⁵ D005910

UMLS via Orphanet ⁷² C0017638

Orphanet ⁵⁸ ORPHA182067

Sources

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to diffuse midline glioma, h3 k27m-mutant and gliosarcoma. An important gene associated with Glial Tumor is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and t cells, and related phenotypes are Increased Akt phosphorylation after EGF stimulation and cellular

Wikipedia : ⁷⁴ Glial tumor is a general term for numerous tumors of the central nervous system, including astrocytomas,... more...

Sources

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1045)

#	Related Disease	Score	Top Affiliating Genes
1	diffuse midline glioma, h3 k27m-mutant	32.1	OLIG2 BRCA2
2	gliosarcoma	31.4	PTEN OLIG2 EGFR
3	diffuse astrocytoma	30.9	OLIG2 EGFR
4	gliomatosis cerebri	30.5	PTEN EGFR
5	malignant astrocytoma	30.3	PTEN OLIG2 EGFR
6	neurofibroma	30.3	PTEN EGFR
7	central nervous system cancer	30.1	PTEN OLIG2 EGFR
8	li-fraumeni syndrome	30.0	PTEN EGFR BRCA2
9	adenocarcinoma	29.8	PTEN EGFR BRCA2
10	neurofibromatosis, type i	29.8	PTEN OLIG2 EGFR BRCA2
11	glioma	29.8	TNC PTEN EGFR BRCA2
12	mixed glioma	29.7	PTEN OLIG2 EGFR
13	giant cell glioblastoma	29.7	PTEN OLIG2 EGFR
14	anaplastic astrocytoma	29.7	PTEN OLIG2 EGFR
15	oligodendroglioma	29.7	PTEN OLIG2 EGFR
16	glioblastoma	29.6	TNC PTEN EGFR BRCA2
17	supratentorial cancer	29.5	OLIG2 EGFR
18	brain cancer	29.4	PTEN OLIG2 EGFR BRCA2
19	pancreatic ductal adenocarcinoma	29.4	PTEN EGFR BRCA2
20	endometrial adenocarcinoma	29.4	PTEN EGFR
21	suppression of tumorigenicity 12	29.2	PTEN EGFR
22	sporadic breast cancer	29.2	PTEN EGFR BRCA2
23	spinal disease	29.2	PTEN OLIG2 EGFR
24	carcinosarcoma	29.2	PTEN EGFR
25	optic nerve glioma	11.5
26	brain stem glioma	11.4
27	childhood brain stem glioma	11.4
28	brain glioma	11.4
29	optic pathway glioma	11.4
30	glioma susceptibility 2	11.4
31	glioma susceptibility 9	11.4
32	glioma susceptibility 3	11.3
33	third ventricle chordoid glioma	11.3
34	chordoid glioma	11.2
35	spinal cord glioma	11.2
36	limbic encephalitis with lgi1 antibodies	11.2
37	subependymal glioma	11.2
38	astroblastoma	11.2
39	childhood optic nerve glioma	11.1
40	mixed neuronal-glial tumor	11.1
41	angiocentric glioma	11.1
42	glioma susceptibility 6	11.1
43	glioma susceptibility 8	11.1
44	glial tumor of neuroepithelial tissue with unknown origin	11.1
45	glioma susceptibility 4	11.1
46	adult brain stem glioma	11.1
47	adult brainstem mixed glioma	11.1
48	nasal glial heterotopia	11.0
49	medulloblastoma	11.0
50	anaplastic oligodendroglioma	11.0

Graphical network of the top 20 diseases related to Glial Tumor:

Sources

Symptoms & Phenotypes for Glial Tumor

GenomeRNAi Phenotypes related to Glial Tumor according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased Akt phosphorylation after EGF stimulation	GR00204-A-2	8.62	PTEN PTPRB

MGI Mouse Phenotypes related to Glial Tumor:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.73	BRCA2 EGFR MIF OLIG2 PTEN PTPRB
2	neoplasm	MP:0002006	9.55	BRCA2 EGFR MIF OLIG2 PTEN
3	nervous system	MP:0003631	9.43	BRCA2 EGFR MIF OLIG2 PTEN TNC
4	normal	MP:0002873	9.02	BRCA2 EGFR MIF PTEN TNC

Sources

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 476)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Levetiracetam

Approved

Phase 4

102767-28-2

441341

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760 44516822

Trametinib

Approved

Phase 4

871700-17-3

11707110

Phenobarbital

Approved, Investigational

Phase 4

50-06-6

4763

Phenytoin

Approved, Vet_approved

Phase 4

57-41-0

1775

Carbamazepine

Approved, Investigational

Phase 4

298-46-4

2554

Lacosamide

Approved

Phase 4

860352-01-8, 175481-36-4

219078

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Topiramate

Approved

Phase 4

97240-79-4

5284627

Lamotrigine

Approved, Investigational

Phase 4

84057-84-1

3878

Zonisamide

Approved, Investigational

Phase 4

68291-97-4

5734

Rufinamide

Approved

Phase 4

106308-44-5

129228

Clobazam

Approved, Illicit

Phase 4

22316-47-8

2789

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Protein Kinase Inhibitors

Phase 4

Psychotropic Drugs

Phase 4

Calcium, Dietary

Phase 4

Hypoglycemic Agents

Phase 4

Analgesics, Non-Narcotic

Phase 4

Analgesics

Phase 4

calcium channel blockers

Phase 4

Sodium Channel Blockers

Phase 4

Diuretics, Potassium Sparing

Phase 4

Antipsychotic Agents

Phase 4

Anti-Anxiety Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Hypnotics and Sedatives

Phase 4

GABA Modulators

Phase 4

GABA Agonists

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

leucovorin

Approved

Phase 3

58-05-9

6006

Dextroamphetamine

Approved, Illicit

Phase 3

51-64-9

5826

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Trioxsalen

Approved

Phase 3

3902-71-4

5585

Heparin

Approved, Investigational

Phase 3

9005-49-6

772 9812414

Dalteparin

Approved

Phase 3

9005-49-6

Tinzaparin

Approved

Phase 3

9041-08-1, 9005-49-6

25244225

Modafinil

Approved, Investigational

Phase 3

68693-11-8

4236

Somatostatin

Approved, Investigational

Phase 2, Phase 3

51110-01-1, 38916-34-6

53481605

Cobalt

Approved, Experimental

Phase 3

7440-48-4

104729

Vinblastine

Approved

Phase 3

865-21-4

13342 241903

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

tannic acid

Approved

Phase 3

1401-55-4

Copper

Approved, Investigational

Phase 2, Phase 3

7440-50-8

27099

Disulfiram

Approved

Phase 2, Phase 3

97-77-8

3117

Ethanol

Approved

Phase 2, Phase 3

64-17-5

702

Interventional clinical trials:

(show top 50) (show all 1185)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection	Completed	NCT02193568	Phase 4
2	Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure	Recruiting	NCT03048084	Phase 4	Levetiracetam;Valproic Acid
3	An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)	Recruiting	NCT03975829	Phase 4	dabrafenib;trametinib
4	Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study	Recruiting	NCT03340506	Phase 4	dabrafenib;trametinib
5	A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma	Not yet recruiting	NCT04650204	Phase 4	Phenobarbital, Phenytoin, Carbamazepine, Valproate, Gabapentin, Pregabalin, Lamotrigine, Topiramate, Leviteracetam, Lacosamide, Zonisamide, Clobazam, Oxcarbezepine, Rufinamide;Perampanel
6	A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas	Not yet recruiting	NCT02496988	Phase 4	Temozolomide
7	Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study	Unknown status	NCT00256425	Phase 3
8	A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)	Unknown status	NCT00045968	Phase 3	Dendritic cell immunotherapy
9	A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial	Unknown status	NCT02363075	Phase 3	Dexamfetamine sulphate;placebo
10	Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma	Unknown status	NCT00278278	Phase 3	cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11	Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
12	Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma	Unknown status	NCT01878266	Phase 3
13	Barrow 5-ALA Intraoperative Confocal Evaluation Trial	Unknown status	NCT01502280	Phase 3	5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
14	Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over	Unknown status	NCT02892708	Phase 3
15	Ultimate Low Grade Glioma Study	Unknown status	NCT00003015	Phase 3	carboplatin;vincristine sulfate
16	Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial	Unknown status	NCT00517959	Phase 3
17	A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Unknown status	NCT01765088	Phase 3	Temozolomide;α-IFN
18	A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)	Completed	NCT00135876	Phase 3	dalteparin
19	A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma	Completed	NCT00003375	Phase 2, Phase 3	lomustine;procarbazine hydrochloride;vincristine sulfate
20	Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV)	Completed	NCT01167322	Phase 3	NPC-07 for oral administration
21	PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC	Completed	NCT01460706	Phase 2, Phase 3	[68Ga]DOTATOC
22	A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma	Completed	NCT03722355	Phase 3	Carmustine
23	Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children.	Completed	NCT01635140	Phase 3
24	A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma	Completed	NCT01781468	Phase 3	armodafinil 150 mg;armodafinil 250 mg
25	NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide	Completed	NCT00717210	Phase 3	Temozolomide
26	Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma	Completed	NCT00820963	Phase 3	temozolomide
27	Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection	Completed	NCT00241670	Phase 3	5-aminolevulinic acid (5-ALA)
28	Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study	Completed	NCT00182819	Phase 3	temozolomide
29	Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study	Completed	NCT00003916	Phase 3
30	A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin]	Completed	NCT00118222	Phase 3	porfimer sodium
31	A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support	Completed	NCT00078988	Phase 3	carboplatin;etoposide;isotretinoin;thiotepa
32	EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY	Completed	NCT00002620	Phase 3	carmustine;chemotherapy;mitolactol
33	Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	Recruiting	NCT00887146	Phase 3	concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
34	International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013)	Recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid
35	Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery	Recruiting	NCT04316039	Phase 2, Phase 3	Temozolomide
36	IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study	Recruiting	NCT03763422	Phase 3	Temozolomide
37	Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study	Recruiting	NCT03534050	Phase 2, Phase 3
38	A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)	Recruiting	NCT03871257	Phase 3	Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
39	A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma	Recruiting	NCT02455245	Phase 3	Carboplatin;Vincristine
40	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation	Recruiting	NCT04164901	Phase 3	AG-881;Matching Placebo
41	A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)	Recruiting	NCT04166409	Phase 3	Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
42	A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Recruiting	NCT03633552	Phase 3	Temozolomide
43	Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma	Recruiting	NCT01649830	Phase 3	Temozolomide
44	A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial.	Recruiting	NCT02444000	Phase 3	PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
45	Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study	Recruiting	NCT03291977	Phase 3	Fluorescéine Sodique Faure
46	A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment	Recruiting	NCT02629757	Phase 3	β-elemene
47	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations	Recruiting	NCT04576117	Phase 3	Selumetinib Sulfate;Vinblastine Sulfate
48	3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial	Active, not recruiting	NCT01479686	Phase 3
49	DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial	Active, not recruiting	NCT02678975	Phase 2, Phase 3	Disulfiram;Alkylating Agents
50	A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas	Active, not recruiting	NCT01236560	Phase 2, Phase 3	Temozolomide;Vorinostat

Search NIH Clinical Center for Glial Tumor

Sources

Genetic Tests for Glial Tumor

Sources

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

⁴⁰

Brain, Endothelial, T Cells, Spinal Cord, Myeloid, Bone Marrow, Cortex

Sources

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30496)

#	Title	Authors	PMID	Year
1	Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. ⁶	Alter BP...Brody LC	16825431	2007
2	Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. ⁶	Reid S...Familial Wilms Tumour Collaboration	15689453	2005
3	Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. ⁶	Hirsch B...D'Andrea AD	14670928	2004
4	A novel germline mutation of PTEN associated with brain tumours of multiple lineages. ⁶	Staal FJ...Staal GE	12085208	2002
5	Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. ⁶¹	Chen H...Chen G	32964440	2021
6	Paris saponin H inhibits the proliferation of glioma cells through the A1 and A3 adenosine receptor‑mediated pathway. ⁶¹	Bi L...Tang H	33537802	2021
7	Glial cell line-derived neurotrophic factor increases matrix metallopeptidase 9 and 14 expression in microglia and promotes microglia-mediated glioma progression. ⁶¹	Huang Y...Kettenmann H	33404121	2021
8	Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells. ⁶¹	Cao F...Yao S	33482186	2021
9	Effect of mtDNA depletion from C6 glioma cells and characteristics of the generated C6ρ0 cells. ⁶¹	Jin Y...Bai B	33576438	2021
10	Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma. ⁶¹	Zhao L...Zhang X	33508290	2021
11	Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma. ⁶¹	Zhao J...Liu P	33296880	2021
12	Circ‑TOP2A acts as a ceRNA for miR‑346 and contributes to glioma progression via the modulation of sushi domain‑containing 2. ⁶¹	Sang J...Li G	33537815	2021
13	Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ⁶¹	Abbaszade Z...Avci CB	33484758	2021
14	Long Non-coding RNA MALAT1 Upregulates ZEB2 Expression to Promote Malignant Progression of Glioma by Attenuating miR-124. ⁶¹	Cheng H...Li Y	33078370	2021
15	CAMTA1, a novel antitumor gene, regulates proliferation and the cell cycle in glioma by inhibiting AKT phosphorylation. ⁶¹	He Z...Chen Y	33316386	2021
16	Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan. ⁶¹	Naz H...Shahzad N	33226123	2021
17	Attention, memory, and executive functions profile in a prospective cohort of patients with malignant glioma. ⁶¹	Loaiza S...Carvajal S	31181969	2021
18	Anti-oncogenic activities exhibited by paracrine factors of MSCs can be mediated by modulation of KITLG and DKK1 genes in glioma SCs in vitro. ⁶¹	Aslam N...Awidi AS	33575478	2021
19	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. ⁶¹	Haque W...Teh BS	33581781	2021
20	Sox2-dependent maintenance of mouse oligodendroglioma involves the Sox2-mediated downregulation of Cdkn2b, Ebf1, Zfp423, and Hey2. ⁶¹	Barone C...Nicolis SK	32975900	2021
21	Sex differences exist in brain renin-angiotensin system-regulating aminopeptidase activities in transplacental ethyl-nitrosourea-induced gliomas. ⁶¹	Ramirez-Exposito MJ...Martinez-Martos JM	33359638	2021
22	An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients. ⁶¹	Xia P...Huang Y	32410107	2021
23	Long noncoding RNA LIFR-AS1 suppresses proliferation, migration and invasion and promotes apoptosis through modulating miR-4262/NF-κB pathway in glioma. ⁶¹	Ding H...Wang C	33070767	2021
24	HSP60 participates in the anti-glioma effects of curcumin. ⁶¹	Bi F...Li Y	33574907	2021
25	Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. ⁶¹	Park YW...Lee SK	32879995	2021
26	RETRACTED ARTICLE: Knock-down of LncRNA-XIST induced glioma cell death and inhibited tumorigenesis by regulating miR-137/SLC1A5 axis-mediated ROS production. ⁶¹	Sun Y...Zhang X	32036410	2021
27	Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells. ⁶¹	Zhang Q...Fu P	33552293	2021
28	New GFAP splice isoform (GFAPµ) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein. ⁶¹	van Bodegraven EJ...Hol EM	33583081	2021
29	X-rays minibeam radiation therapy at a conventional irradiator: Pilot evaluation in F98-glioma bearing rats and dose calculations in a human phantom. ⁶¹	Sotiropoulos M...Prezado Y	33511291	2021
30	[Corrigendum] Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α. ⁶¹	Yang XS...Cheng SX	33495805	2021
31	Transcription Factor ELF1 Activates MEIS1 Transcription and Then Regulates the GFI1/FBW7 Axis to Promote the Development of Glioma. ⁶¹	Cheng M...Wu Y	33473327	2021
32	Effect of Ras-guanine nucleotide release factor 1-mediated H-Ras/ERK signaling pathway on glioma. ⁶¹	Pan YH...Li X	33412149	2021
33	Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma. ⁶¹	Minasi S...Buttarelli FR	33128602	2021
34	Phosphorylated form of pyruvate dehydrogenase α1 mediates tumor necrosis factor α-induced glioma cell migration. ⁶¹	Yang Z...Wang D	33574915	2021
35	Insulin signaling mediates neurodegeneration in glioma. ⁶¹	Jarabo P...Casas-Tinto S	33526430	2021
36	Genome-wide translation patterns in gliomas: An integrative view. ⁶¹	Hajj GNM...Roffe M	33321181	2021
37	Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma. ⁶¹	Cindil E...Tali T	32821962	2021
38	Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review. ⁶¹	Lasocki A...Thust SC	32840682	2021
39	Epilepsy enhance global efficiency of language networks in right temporal lobe gliomas. ⁶¹	Fang S...Jiang T	33464718	2021
40	18F-FDG PET/CT in Anti-Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis: Typical Pattern and Follow-up. ⁶¹	Caquot PA...Morland D	33323741	2021
41	A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening. ⁶¹	Zhang L...Liu Z	33309780	2021
42	Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas. ⁶¹	Jia L...Zhang N	33332981	2021
43	Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation. ⁶¹	Maitre P...Jalali R	32917486	2021
44	Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors: A randomized controlled trial. ⁶¹	Zhao X	33592815	2021
45	Diffuse midline glioma presenting with central sleep apnea and pulmonary hypertension in a 4-year-old patient: a case report. ⁶¹	Huang SW...Wu MH	33006310	2021
46	XPG gene polymorphisms and glioma susceptibility: a two-centre case-control study. ⁶¹	Yuan L...Zeng L	33393424	2021
47	Stroke Mimics and Chameleons from the Radiological Viewpoint of Glioma Diagnosis. ⁶¹	Sasagawa A...Mikuni N	33390559	2021
48	Mucosal thickening of the maxillary sinus is frequently associated with diffuse glioma patients and correlates with poor survival prognosis of GBM patients: comparative analysis to meningioma patients. ⁶¹	Saito T...Kawamata T	33537891	2021
49	Lactoferrin/phenylboronic acid-functionalized hyaluronic acid nanogels loading doxorubicin hydrochloride for targeting glioma. ⁶¹	Zhang M...Xiao Y	33278970	2021
50	Microglial Exosome miR-7239-3p Promotes Glioma Progression by Regulating Circadian Genes. ⁶¹	Li X...Wang Z	33528793	2021

Sources

Genes for Glial Tumor

Genes related to Glial Tumor (2 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PTEN	Phosphatase And Tensin Homolog	Protein Coding	432.07	Pathogenic ⁶ Likely pathogenic ⁶ GeneCards inferred via : Publications (show sections)
2	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	425	Pathogenic ⁶ Risk factor ⁶	15689453 14670928 16825431
3	EGFR	Epidermal Growth Factor Receptor	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)
4	MIF	Macrophage Migration Inhibitory Factor	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)
5	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)
6	PTPRB	Protein Tyrosine Phosphatase Receptor Type B	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)
7	TNC	Tenascin C	Protein Coding	7.07	GeneCards inferred via : Publications (show sections)

Sources

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

⁶ (show top 50) (show all 78)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	BRCA2	NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter)	SNV	Pathogenic	52808	rs397508045	13:32893238-32893238	13:32319101-32319101
2	BRCA2	NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter)	SNV	Pathogenic	51041	rs80358391	13:32893246-32893246	13:32319109-32319109
3	BRCA2	NM_000059.3(BRCA2):c.1399A>T (p.Lys467Ter)	SNV	Pathogenic	51118	rs80358427	13:32907014-32907014	13:32332877-32332877
4	BRCA2	NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter)	SNV	Pathogenic	37819	rs80358557	13:32911601-32911601	13:32337464-32337464
5	BRCA2	NM_000059.3(BRCA2):c.4243G>T (p.Glu1415Ter)	SNV	Pathogenic	37890	rs397507327	13:32912735-32912735	13:32338598-32338598
6	BRCA2	NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter)	SNV	Pathogenic	37936	rs80358721	13:32913457-32913457	13:32339320-32339320
7	PTEN	NM_000314.7(PTEN):c.517C>T (p.Arg173Cys)	SNV	Pathogenic	189500	rs121913293	10:89711899-89711899	10:87952142-87952142
8	BRCA2	NM_000059.3(BRCA2):c.5791C>T (p.Gln1931Ter)	SNV	Pathogenic	51939	rs80358807	13:32914283-32914283	13:32340146-32340146
9	BRCA2	NM_000059.4(BRCA2):c.6656C>G (p.Ser2219Ter)	SNV	Pathogenic	52149	rs80358893	13:32915148-32915148	13:32341011-32341011
10	BRCA2	NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter)	SNV	Pathogenic	38076	rs80358920	13:32920978-32920978	13:32346841-32346841
11	BRCA2	NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe)	SNV	Pathogenic	52430	rs80359014	13:32936733-32936733	13:32362596-32362596
12	BRCA2	NM_000059.4(BRCA2):c.7988A>T (p.Glu2663Val)	SNV	Pathogenic	52462	rs80359031	13:32937327-32937327	13:32363190-32363190
13	BRCA2	NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His)	SNV	Pathogenic	52515	rs41293511	13:32937506-32937506	13:32363369-32363369
14	BRCA2	NM_000059.4(BRCA2):c.8488-1G>A	SNV	Pathogenic	38164	rs397507404	13:32945092-32945092	13:32370955-32370955
15	BRCA2	NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=)	SNV	Pathogenic	38215	rs28897756	13:32954050-32954050	13:32379913-32379913
16	BRCA2	NM_000059.4(BRCA2):c.9294C>G (p.Tyr3098Ter)	SNV	Pathogenic	38229	rs80359200	13:32968863-32968863	13:32394726-32394726
17	BRCA2	NM_000059.4(BRCA2):c.9382C>T (p.Arg3128Ter)	SNV	Pathogenic	52826	rs80359212	13:32968951-32968951	13:32394814-32394814
18	PTEN	NM_000314.7(PTEN):c.253+2T>A	SNV	Pathogenic	468676	rs1224040268	10:89690848-89690848	10:87931091-87931091
19	PTEN	NM_000314.7(PTEN):c.860C>G (p.Ser287Ter)	SNV	Pathogenic	216987	rs863224909	10:89720709-89720709	10:87960952-87960952
20	PTEN	NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter)	SNV	Pathogenic	7833	rs121909231	10:89720852-89720852	10:87961095-87961095
21	BRCA2	NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter)	SNV	Pathogenic	37989	rs41293497	13:32914174-32914174	13:32340037-32340037
22	BRCA2	NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=)	SNV	Pathogenic	38215	rs28897756	13:32954050-32954050	13:32379913-32379913
23	BRCA2	NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter)	SNV	Pathogenic	51952	rs80358814	13:32914349-32914349	13:32340212-32340212
24	BRCA2	NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter)	SNV	Pathogenic	51129	rs80358435	13:32893291-32893291	13:32319154-32319154
25	BRCA2	NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter)	SNV	Pathogenic	38099	rs80358972	13:32930609-32930609	13:32356472-32356472
26	PTEN	NM_000314.7(PTEN):c.404T>A (p.Ile135Lys)	SNV	Likely pathogenic	428235	rs370795352	10:89692920-89692920	10:87933163-87933163
27	PTEN	NM_000314.7(PTEN):c.701G>A (p.Arg234Gln)	SNV	risk factor	7840	rs121909235	10:89717676-89717676	10:87957919-87957919
28	BRCA2	NM_000059.4(BRCA2):c.658_659del	Deletion	risk factor	9342	rs80359604	13:32903605-32903606	13:32329468-32329469
29	BRCA2	NM_000059.4(BRCA2):c.5645C>G (p.Ser1882Ter)	SNV	risk factor	9346	rs80358785	13:32914137-32914137	13:32340000-32340000
30	PTEN	NM_000314.8(PTEN):c.235G>A (p.Ala79Thr)	SNV	Uncertain significance	41682	rs202004587	10:89690828-89690828	10:87931071-87931071
31	PTEN	NM_000314.7(PTEN):c.862G>A (p.Glu288Lys)	SNV	Uncertain significance	484603	rs1554825528	10:89720711-89720711	10:87960954-87960954
32	PTEN	NM_000314.8(PTEN):c.892C>G (p.Gln298Glu)	SNV	Uncertain significance	127695	rs371387815	10:89720741-89720741	10:87960984-87960984
33	BRCA2	NM_000059.3(BRCA2):c.7625C>T (p.Thr2542Met)	SNV	Uncertain significance	96854	rs80358989	13:32931886-32931886	13:32357749-32357749
34	BRCA2	NM_000059.3(BRCA2):c.7051G>A (p.Ala2351Thr)	SNV	Uncertain significance	52256	rs80358930	13:32929041-32929041	13:32354904-32354904
35	PTEN	NM_000314.8(PTEN):c.882T>G (p.Ser294Arg)	SNV	Uncertain significance	127693	rs143335584	10:89720731-89720731	10:87960974-87960974
36	PTEN	NM_001126049.2(KLLN):c.-736G>C	SNV	Uncertain significance	488964	rs1554889801	10:89622980-89622980	10:87863223-87863223
37	PTEN	NM_001126049.2(KLLN):c.-792C>T	SNV	Uncertain significance	127663	rs587779982	10:89623036-89623036	10:87863279-87863279
38	PTEN	NM_001126049.2(KLLN):c.-828C>T	SNV	Uncertain significance	187362	rs786203674	10:89623072-89623072	10:87863315-87863315
39	PTEN	NM_001126049.2(KLLN):c.-1039G>A	SNV	Uncertain significance	127682	rs587779999	10:89623283-89623283	10:87863526-87863526
40	PTEN	NM_000314.4(PTEN):c.-868G>C	SNV	Uncertain significance	141949	rs587782133	10:89623358-89623358	10:87863601-87863601
41	PTEN	NM_000314.7(PTEN):c.-834C>T	SNV	Uncertain significance	127676	rs587779994	10:89623392-89623392	10:87863635-87863635
42	PTEN	NM_000314.7(PTEN):c.-821G>T	SNV	Uncertain significance	234510	rs587779993	10:89623405-89623405	10:87863648-87863648
43	PTEN	NM_000314.7(PTEN):c.-764G>A	SNV	Uncertain significance	7844	rs587776674	10:89623462-89623462	10:87863705-87863705
44	BRCA2	NM_000059.3(BRCA2):c.1433C>A (p.Thr478Lys)	SNV	Uncertain significance	96764	rs431825282	13:32907048-32907048	13:32332911-32332911
45	BRCA2	NM_000059.3(BRCA2):c.2122T>A (p.Ser708Thr)	SNV	Uncertain significance	51246	rs80358488	13:32910614-32910614	13:32336477-32336477
46	BRCA2	NM_000059.3(BRCA2):c.2186T>C (p.Ile729Thr)	SNV	Uncertain significance	96780	rs431825296	13:32910678-32910678	13:32336541-32336541
47	BRCA2	NM_000059.4(BRCA2):c.2405A>G (p.Asn802Ser)	SNV	Uncertain significance	234566	rs876661089	13:32910897-32910897	13:32336760-32336760
48	BRCA2	NM_000059.3(BRCA2):c.2908G>A (p.Asp970Asn)	SNV	Uncertain significance	37806	rs397507295	13:32911400-32911400	13:32337263-32337263
49	BRCA2	NM_000059.3(BRCA2):c.3808G>A (p.Val1270Ile)	SNV	Uncertain significance	231069	rs876658938	13:32912300-32912300	13:32338163-32338163
50	BRCA2	NM_000059.4(BRCA2):c.3835A>G (p.Asn1279Asp)	SNV	Uncertain significance	51534	rs80358626	13:32912327-32912327	13:32338190-32338190

Sources

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Sources

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	11.93	PTEN EGFR BRCA2
2	MicroRNAs in cancer ³⁶	11.62	TNC PTEN EGFR
3	Adherens junction ³⁶	11.17	PTPRB EGFR
4	Central carbon metabolism in cancer ³⁶	11.1	PTEN EGFR
5	Integrated Breast Cancer Pathway ¹	10.99	PTEN EGFR BRCA2

Sources

GO Terms for Glial Tumor

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	learning or memory	GO:0007611	9.26	PTEN EGFR
2	positive regulation of phosphorylation	GO:0042327	9.16	MIF EGFR
3	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.13	PTEN MIF EGFR
4	negative regulation of cell aging	GO:0090344	8.62	PTEN MIF

Molecular functions related to Glial Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.02	PTEN OLIG2 MIF EGFR BRCA2

Sources

Sources for Glial Tumor

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia